Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06285240 · ClinicalTrials.gov registry record · Phase 1
Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT06285240 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 28 participants.
The verdict
NCT06285240, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the safety and efficacy of MK-1167 administered to participants with Alzheimer's Disease (AD) receiving stable Donepezil treatment.
Interventions
- DRUG Placebo
- DRUG Donepezil
- DRUG MK-1167
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2024-03-28 |
| Est. Completion | 2024-09-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06285240
The ClinicalTrials.gov registry entry for NCT06285240 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06285240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06285240 about?
NCT06285240 is a clinical study titled "Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia Taking Stable Donepezil Treatment (MK-1167-007)". The main purpose of this study is to assess the safety and efficacy of MK-1167 administered to participants with Alzheimer's Disease (AD) receiving stable Donepezil treatment.
What is the current status of trial NCT06285240?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2024-03-28. Estimated completion is 2024-09-23.
What interventions are being tested in trial NCT06285240?
The interventions under investigation include: Placebo (DRUG), Donepezil (DRUG), MK-1167 (DRUG).
Who is sponsoring clinical trial NCT06285240?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.